Stock Ratings / Health Care / KTTA / options

BIVI (32) RKTO (40) HIND (29) JAGX (28) ⌘ Pro Terminal →

Pasithea Therapeutics Corp. (KTTA) Options Positioning, Max Pain & Unusual Sweeps

$0.37 +0.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.37

Pasithea Therapeutics Corp. (KTTA) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $12.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KTTA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KTTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Pasithea Therapeutics Corp. (NASDAQ: KTTA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.37 (+0.16% 1D, market cap $12.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KTTA ranks #473 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KTTA compare to BIVI and RKTO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KTTA carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BIVI (BioVie Inc. (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M) and RKTO (Rocket One Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.1M). Among the 5-stock peer group, KTTA leads on earnings multiple (N/A) while KTTA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KTTA?

▼

Per KTTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001841330), Pasithea Therapeutics Corp. generated $0 in revenue, -$20.4M in net income, and -$15.2M in free cash flow against $60.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.37 (-0.16%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KTTA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY KTTA SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 34.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.42-2.4% Next Q

Q2 (-2Q)

Grade D$0.41-2.4% Next Q

Q3 (-1Q)

Grade D$0.40-7.5% Next Q

Current

Grade D-$0.37-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KTTA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KTTA currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.48) and Max Pain ($0.39) forces dealer call-delta covering toward $2.16.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KTTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KTTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (KTTA)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for KTTA.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KTTA)

✓Walkthrough of KTTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KTTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -56.47%🛡️ HOLDING TREND SUPPORT

2026-11-03O $0.37H $0.37L $0.37C $0.37VOL 100.2K

RES: $0.48SUP: $0.33SMA50: $0.48SMA200: $0.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KTTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KTTA Butterfly Map → + Track KTTA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KTTA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KTTA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KTTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KTTA)

Health Care Rank #473 of 1016 ⚔️ BIVI vs KTTA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KTTA vs. BIVI, RKTO, HIND, JAGX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pasithea Therapeutics Corp. (KTTA) ranks #473 by composite RQD confidence (40/100, grade D-) and #875 by equity capitalization ($12.4M). Within this direct 5-issuer industry benchmark cohort, KTTA leads on earnings valuation at N/A trailing P/E, while KTTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KTTA currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KTTA ACTIVE Pasithea Therapeutics Corp.	D-	40/100	—	—	-35.0%	+0.16%	$12.4M	Benchmark Subject
BIVI BioVie Inc. (Class A)	E	32/100	—	—	-35.0%	+3.62%	$12.4M	/bivi-vs-ktta →
RKTO Rocket One Inc.	D-	40/100	—	—	-35.0%	-5.60%	$12.1M	/rkto-vs-ktta →
HIND Vyome Holdings Inc.	E	29/100	—	68.4%	-35.0%	+2.86%	$12.6M	/hind-vs-ktta →
JAGX Jaguar Health Inc.	E	28/100	—	67.2%	-35.0%	-20.59%	$12.6M	/jagx-vs-ktta →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001841330

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pasithea Therapeutics Corp. (KTTA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$20.4M, operating cash flow of -$15.2M, and free cash flow of -$15.2M (-9.3% YoY). On the balance sheet, KTTA closed FY2025 with $60.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$20.4M	-$15.2M	-$15.2M	$60.2M	—
FY2024 (FY)	2024-12-31	$0	-$13.9M	-$13.9M	-$13.9M	$16.1M	—
FY2023 (FY)	2023-12-31	$0	-$16.0M	—	—	—	—

3. KTTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KTTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KTTA compare to BIVI and RKTO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KTTA?

Where is KTTA trading relative to its 50-day, 200-day, and 52-week technical levels?

KTTA last traded at $0.37 (+0.16% on volume of 100,162 shares), positioning the stock -22.92% below its 50-day simple moving average ($0.48) and -41.27% below its 200-day simple moving average ($0.63). Across its 52-week range of $0.28 to $2.06, KTTA sits at the 5.1% percentile with a 14-day RSI of 34.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).

KTTA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is KTTA's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for KTTA.

Direct Sub-Reports: KTTA RQD Cockpit KTTA 12M Forecast KTTA Earnings & Move KTTA Dividends & DRIP KTTA Insiders & 13F KTTA Whale Options KTTA Profit Sankey KTTA News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KTTA — Pasithea Therapeutics Corp.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:51:17Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, KTTA scores 40 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 8 / 20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 8 / 20 (institutional accumulation and options positioning), Insider Conviction at 5 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 9 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are cash generation and insider conviction, which means the rating does not currently point to self-funding operations or strong insider signaling. The forensic pillar is the relative bright spot, though a Piotroski F-Score of 2/9 is still low. Per the same rating, the upside case depends on flow and sentiment improving, while valuation tradeoffs center on a company reporting no revenue and negative returns on capital.

Business

Pasithea Therapeutics Corp. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, the issuer's revenue in the reported periods is $0.0M, indicating no reported product or service revenue in the source data. Not available in source data for specific products, customers, or monetization model beyond clinical-stage activity referenced in news headlines.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-20.9M	$-20.4M	N/A	$-15.2M	$55.2M	N/A
FY 2024	$0.0M	$-14.2M	$-13.9M	N/A	$-13.9M	$6.9M	N/A
FY 2023	$0.0M	$-16.0M	$-16.0M	N/A	N/A	N/A	N/A

Per the SEC financials, operating and net losses widened from FY 2023 to FY 2025, and FY 2025 free cash flow was $-15.2M. Gross, operating, and net margins are all reported as 0% in the market data. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, and the Piotroski F-Score is 2/9. Cash increased to $55.2M in FY 2025 from $6.9M in FY 2024; debt is Not available in source data, while Debt/Equity is reported as 0.5 in the RQD rating.

Recent Catalysts & News Wire Analysis

Per the recent news wire, catalysts include a planned virtual KOL event on NF1 treatment dated November 4, 2026, and a headline reporting positive PAS-004 clinical data from a Phase 1 advanced cancer study presented at ESMO Congress 2026. Price-action headlines report a 3.40% slip to $0.41 and a 19.02% jump to $0.49, indicating high short-term volatility. Watch items include the reported 52-week low of $0.28 and the microcap market capitalization. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are present in the source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links. Not available in source data for upstream suppliers, downstream customers, or sector correlations beyond the sector and industry classification. A prospective investor should note that the absence of mapped dependencies means second-order effects cannot be assessed from this dataset.

Open Questions

What are the terms, cash runway, and burn assumptions behind the reported $55.2M cash position relative to the FY 2025 $-15.2M free cash flow?
What is the total debt balance, given that debt is listed as N/A while Debt/Equity is reported at 0.5?
What is the clinical and regulatory timeline for PAS-004 and the NF1 program referenced in news headlines?
Who are the institutional holders and insiders, and what are their recent transactions?
Why are EPS and P/E unavailable, and what share count underlies the $12.3M market capitalization?

KTTA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pasithea Therapeutics Corp. (KTTA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KTTA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago

Pasithea Therapeutics Corp. (KTTA) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Pasithea Therapeutics Corp. (KTTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 21h ago

Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026

Yahoo Finance report covering Pasithea Therapeutics Corp. (KTTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Pasithea Therapeutics (KTTA) Slips 3.40% to $0.41 as Micro-Cap Biotech Holds Near Support - Aggressive Growth Picks

https://www.siam.in/ report covering Pasithea Therapeutics Corp. (KTTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST www.dars.gov.et • 1d ago

Pasithea Therapeutics (KTTA) Jumps 19.02% to $0.49 as Micro-Cap Biotech Tests Upper Range - Inside Day Breakout

www.dars.gov.et report covering Pasithea Therapeutics Corp. (KTTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026

Yahoo Finance report covering Pasithea Therapeutics Corp. (KTTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Pasithea Therapeutics Corp. (KTTA) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Pasithea Therapeutics Corp. (KTTA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 11d ago

Pasithea Therapeutics Presents Phase I Dose-Escalation Trial Of PAS-004 Inhibitor; Announces No Dose Limiting Toxicities Seen; No Participant Discontinued PAS-004; No Grade 3, Higher Observed

Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KTTA Bull vs. Bear Conversation Board — What's Your Call at $0.37?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KTTA 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.33 (-10.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is KTTA (D- • RQD 40/100) a Buy at $0.37?

Welcome to the KTTA (Pasithea Therapeutics Corp.) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.28 (-24.3%)

Spot @ $0.37

Pump the brakes on KTTA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on KTTA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Pasithea Therapeutics Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.45 (+21.6%)

Spot @ $0.37

KTTA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on KTTA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.37 (52-wk range $0.28 - $2.06), any beat on forward guidance forces shorts and underweight funds to chase.